November 21, 2023 News by Steve Bryson, PhD Vumerity reduces relapses, lesions over 2 years: EVOLVE-MS-1 study Nearly two years of treatment with Vumerity (diroximel fumarate) significantly reduced relapse rates by more than 80% in people with relapsing-remitting multiple sclerosis (RRMS), according to the final published details of the EVOLVE-MS-1 clinical trial. MRI scans also showed the number of active inflammatory lesions and new…
October 25, 2022 News by Marisa Wexler, MS Risk of MS Activity After DMT Stop Greater With RRMS, Younger Age Note: This story was updated Oct. 31, 2022, to correct that in the six months after treatment discontinuation, relapses were reported in 18.8% of RMMS patients and 3.5% of those with SPMS. When multiple sclerosis (MS) patients stop their disease-modifying treatment, the risk of relapses and disease activity on…
September 2, 2022 News by Marta Figueiredo, PhD Delayed Ocrevus Infusion May Increase MRI-based RRMS Risk An extended interval between maintenance doses of OcrevusĀ (ocrelizumab) may increase the risk of MRI-based disease activity in people with relapsing-remitting multiple sclerosisĀ (RRMS), according to a real-world, multicenter study in Italy. In fact, an extended interval dosing (by one month or longer) was associated with a fivefold higher risk…
March 25, 2021 News by Vanda Pinto, PhD Early MRI Findings May Predict Disease Worsening in Children with MS Abnormalities detected on MRI scans at the onset and within the first two years of disease may predict disability worsening in children with multiple sclerosis (MS), a nine-year study reports. Specifically, damage in the spinal cord, brain, and optic nerve plays a major role in predicting outcomes in these…
August 27, 2019 News by Ana Pena PhD Central Vein Sign Maintains Potential as MS Diagnostic Marker, European Study Shows Detecting changes to the brain’s central vein using common magnetic resonance imaging (MRI) scans is a useful and accurate strategy to enhanceĀ diagnosis of multiple sclerosis (MS), a new study shows. Analysis of more than 4,000 brain lesions, obtained from contrast-enhanced MRI scans collected from eight neuroimaging European…
February 20, 2017 News by Patricia Silva, PhD Ozanimod Reduces Multiple Sclerosis Relapse Rate, Phase 3 Trial Shows A Phase 3 clinical trial evaluating the safety and effectiveness of ozanimod (RPC-1063) in patients withĀ relapsing multiple sclerosis (RMS)Ā shows treatment reduced the disease’s annualized relapse rate (ARR), researchers reported. The Phase 3 SUNBEAM trial (NCT02294058)Ā testedĀ ozanimod, anĀ oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator designed to…
April 6, 2016 News by Patricia Silva, PhD MS-associated Myelitis Can Be Identified Early Through MRI Scans, Study Reports Researchers reported that patients with myelitis who later develop multiple sclerosis (MS) might be distinguished from others with myelitis by a number of characteristics, like the location and size of spinal cord lesions, a finding that might help clinicians diagnose MS and initiate treatment at an early stage. Myelitis, an…